T. Shun

发表

Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus.

Paul A Johnston, Billy W Day, Tong Ying Shun, 2012, Assay and drug development technologies.

Biologically Relevant Heterogeneity: Metrics and Practical Insights

Chakra Chennubhotla, Albert Gough, Mark E Schurdak, 2017, SLAS discovery : advancing life sciences R & D.

Automated High-Content Live Animal Drug Screening Using C. elegans Expressing the Aggregation Prone Serpin α1-antitrypsin Z

J. Lazo, G. Silverman, P. Johnston, 2010, PloS one.

A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens.

M. Schurdak, A. Gough, T. Shun, 2016, Methods.

Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents.

Peter Wipf, Paul A Johnston, Tong Ying Shun, 2008, Assay and drug development technologies.

Validation of a high throughput screening assay to identify small molecules that target the eukaryotic replicative helicase.

M. Schurdak, T. Shun, A. Schwacha, 2022, SLAS discovery : advancing life sciences R & D.

The Microphysiology Systems Database for Analyzing and Modeling Compound Interactions with Human and Animal Organ Models.

D. L. Taylor, L. Vernetti, A. Gough, 2016, Applied in vitro toxicology.

Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington’s Disease Model through the Application of Quantitative Systems Pharmacology

Hongchun Li, D. L. Taylor, I. Bahar, 2017, Scientific Reports.

Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes

Adrian V. Lee, D. L. Taylor, S. Oesterreich, 2018, Oncology.

Development and Optimization of a High-Content Analysis Platform to Identify Suppressors of Lamin B1 Overexpression as a Therapeutic Strategy for Autosomal Dominant Leukodystrophy

A. Gough, T. Shun, A. Vogt, 2020, SLAS discovery : advancing life sciences R & D.

A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies

Daniel E. Lefever, D. L. Taylor, I. Bahar, 2022, Metabolites.

Exploiting Analysis of Heterogeneity to Increase the Information Content Extracted from Fluorescence Micrographs of Transgenic Zebrafish Embryos.

N. Hukriede, A. Gough, T. Shun, 2017, Assay and drug development technologies.

Implementation of the NCI-60 Human Tumor Cell Line Panel to Screen 2260 Cancer Drug Combinations to Generate >3 Million Data Points Used to Populate a Large Matrix of Anti-Neoplastic Agent Combinations (ALMANAC) Database

P. Johnston, T. Shun, David A. Close, 2018, SLAS discovery : advancing life sciences R & D.

Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.

Peter R. McDonald, I. Pollack, J. Lazo, 2010, Neurosurgical focus.

Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets

Peter R. McDonald, I. Pollack, J. Lazo, 2010, Journal of Neuroscience Methods.

HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.

G. M. Wilson, P. Wipf, J. Grandis, 2015, Assay and drug development technologies.

Identification of Survival Genes in Human Glioblastoma Cells Using siRNA Screening

Peter R. McDonald, I. Pollack, J. Lazo, 2009 .

Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

D. L. Taylor, K. Giuliano, C. Strock, 2010, Assay and drug development technologies.

Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.

G. M. Wilson, J. Nelson, P. Wipf, 2016, Assay and drug development technologies.

A High-Throughput Assay for DNA Replication Inhibitors Based upon Multivariate Analysis of Yeast Growth Kinetics

M. Schurdak, A. Gough, T. Shun, 2019, SLAS discovery : advancing life sciences R & D.

Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule Screen

John S. Lazo, Peter Wipf, Elizabeth R. Sharlow, 2009, PLoS neglected tropical diseases.

In vitro platforms for evaluating liver toxicity

Manjunath Hegde, Albert Gough, Lawrence Vernetti, 2014, Experimental biology and medicine.

A 3D Microfluidic Liver Model for High Throughput Compound Toxicity Screening in the OrganoPlate®.

Anthony D. Saleh, L. Vernetti, A. Gough, 2020, Toxicology.

Identification of Survival Genes in Human Glioblastoma Cells by Small Interfering RNA Screening

Fang Zhang, Nikhil G Thaker, Peter R McDonald, 2009, Molecular Pharmacology.

Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.

P. Wipf, J. Lazo, P. Johnston, 2007, Assay and drug development technologies.

Development and optimization of high-throughput in vitro protein phosphatase screening assays

J. Lazo, P. Johnston, Sunita Shinde, 2007, Nature Protocols.

Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1.

J. Lazo, T. Shun, E. Sharlow, 2007, Assay and drug development technologies.

Alkylation Sensitivity Screens Reveal a Conserved Cross-species Functionome

I. Pollack, T. Begley, J. Lazo, 2012, Molecular Cancer Research.

Identification of Druggable Targets for Radiation Mitigation Using a Small Interfering RNA Screening Assay

J. Lazo, J. Greenberger, T. Shun, 2012, Radiation research.

Cross-species Functionome Alkylation Sensitivity Screens Reveal a Conserved

I. Pollack, T. Begley, J. Lazo, 2012 .

Functionome Alkylation Sensitivity Screens Reveal a Conserved Cross-species

I. Pollack, T. Begley, J. Lazo, 2012 .

Identification of Chemosensitivity Nodes for Vinblastine through Small Interfering RNA High-Throughput Screens

I. Pollack, J. Lazo, T. Shun, 2011, Journal of Pharmacology and Experimental Therapeutics.

Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery

Adrian V. Lee, Timothy R. Lezon, Jennifer R. Grandis, 2014, PloS one.

Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors

Daniel E. Lefever, A. Soto-Gutiérrez, L. Vernetti, 2021, Experimental biology and medicine.

High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.

C. Strock, P. Johnston, Yun Hua, 2014, Assay and drug development technologies.

Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy

P. Empey, P. Johnston, T. Shun, 2019, SLAS discovery : advancing life sciences R & D.

Integrating Analysis of Cellular Heterogeneity in High-Content Dose-Response Studies.

D. L. Taylor, M. Schurdak, A. Gough, 2018, Methods in molecular biology.

High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.

J. Grandis, J. Lazo, P. Johnston, 2018, Methods in molecular biology.

Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.

P. Wipf, J. Lazo, P. Johnston, 2009, Assay and drug development technologies.

Identifying Actives from HTS Data Sets

Paul A Johnston, Tong Ying Shun, John S Lazo, 2011, Journal of biomolecular screening.

Discovery of Diverse Small Molecule Chemotypes with Cell-Based PKD1 Inhibitory Activity

P. Wipf, J. Lazo, T. Shun, 2011, PloS one.

High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

J. Grandis, J. Lazo, P. Johnston, 2014, Assay and drug development technologies.

Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans

Manjunath Hegde, Albert Gough, Lawrence Vernetti, 2013, Stem Cell Research & Therapy.

Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments.

Peter Wipf, Paul A Johnston, Tong Ying Shun, 2010, Assay and drug development technologies.

Implementation of a 220,000-Compound HCS Campaign to Identify Disruptors of the Interaction between p53 and hDM2 and Characterization of the Confirmed Hits

D. L. Taylor, K. Giuliano, C. Strock, 2010, Journal of biomolecular screening.

and hDM2 and Characterization of the Confirmed Hits Implementation of a 220,000-Compound HCS Campaign to Identify Disruptors of the Interaction between p53

K. Giuliano, C. Strock, P. Johnston, 2013 .

Applications of the microphysiology systems database for experimental ADME-Tox and disease models† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9lc01047e

Albert Gough, Lawrence Vernetti, Mark E. Schurdak, 2019, bioRxiv.

Identification of Chemosensitivity Nodes for Vinblastine through Small Interfering RNA High-Throughput Screens

I. Pollack, J. Lazo, T. Shun, 2011, Journal of Pharmacology and Experimental Therapeutics.

Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.

G. M. Wilson, J. Nelson, P. Wipf, 2016, Assay and drug development technologies.

HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus.

Michael C. Myers, Jeffrey W. Smith, A. Strongin, 2007, Assay and drug development technologies.

High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.

J. Grandis, J. Lazo, P. Johnston, 2018, Methods in molecular biology.

In vitro platforms for evaluating liver toxicity

O. B. Usta, A. Bakan, M. Yarmush, 2014, Experimental biology and medicine.

Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans

A. Bakan, O. Berk Usta, M. Yarmush, 2013, Stem Cell Research & Therapy.